To compare bone mineral density ( BMD ) changes over 96 weeks in adults virologically failing standard first-line therapy , randomized to raltegravir plus lopinavir/ritonavir ( RAL + LPV/r ) or conventional 2-3 nucleoside/nucleotide reverse transcriptase inhibitors [ N ( t ) RTIs ] + LPV/r second-line therapy .